V160G (p.Val160Gly) variant of MFN2 (Mitofusin-2)

V160G (p.Val160Gly) in MFN2 (Mitofusin-2) is a missense change. Clinical records from ClinVar, EBI, and UniProt describe it as likely pathogenic in the context of Charcot-Marie-Tooth disease type 2A2. The available variant effect predictions contribute to a CATVariant prioritization score of 0.88 / 1. The record also includes published literature and structural context.

V160G (p.Val160Gly) variant details